Brief: Compass Pathways Announces Durable Improvement In Symptoms Through 12 Weeks In Open-Label Phase 2 Study Of Comp360 Psilocybin In Post-Traumatic Stress Disorder
08/05/2024 12:27
May 8 (Reuters) - Compass Pathways PLC CMPS.O :
* COMPASS PATHWAYS ANNOUNCES DURABLE IMPROVEMENT IN SYMPTOMS
THROUGH 12 WEEKS IN OPEN-LABEL PHASE 2 STUDY OF COMP360
PSILOCYBIN IN POST-TRAUMATIC STRESS DISORDER
* COMPASS PATHWAYS PLC: STUDY MET PRIMARY SAFETY ENDPOINT;
ADMINISTRATION WAS WELL TOLERATED, WITH NO SERIOUS ADVERSE
EVENTS OBSERVED
Source text for Eikon: ID:nGNX9jTM8z
Further company coverage: CMPS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications